Search results
Showing 151 to 157 of 157 results for pembrolizumab
Draft guidance published today (8 March 2022) by NICE for public consultation does not recommend pembrolizumab plus chemotherapy for treating triple negative breast cancer that has spread to other parts of the body.
Around 1,500 people aged 12 years and over with melanoma are set to benefit from pembrolizumab (also called Keytruda and made by MSD), a drug that reduces the chance of it returning, following final draft NICE guidance published today (23 September 2022).
Hundreds of people with cervical cancer are set to receive the first immunotherapy drug for an advanced form of the disease as NICE publishes final draft guidance today (Wednesday 29 March 2023) recommending its use in the Cancer Drugs Fund (CDF).
Colorectal cancer patients with rare mutations to benefit from life-extending treatment
NICE recommends pembrolizumab for colorectal cancer patients with rare mutations
NICE recommends step-change targeted treatment for people with early breast cancer
Around 4,000 people are set to benefit from a step-change in treatment for early breast cancer following today’s (17 June 2022) provisional approval by NICE of abemaciclib in combination with hormone therapy as an option after surgery.
NICE final draft guidance adds further treatment option for triple-negative breast cancer
NICE has today (8 November 2022) published final draft guidance which recommends pembrolizumab as an option for people with a type of breast cancer called triple-negative breast cancer.
Thousands of lung cancer patients to benefit from life-extending treatment
A potentially life-extending treatment for some people with non-squamous, non-small-cell lung cancer (NSCLC) will now be available on the NHS following its approval by NICE in draft guidance published today.